Key Industry Developments: In October 2025 , Eli Lilly and Company achieved its fourth Phase III success with its oral GLP-1 receptor agonist, orforglipron, in type 2 diabetes trials
You might notice slightly reduced appetite by evening, but changes are subtle
Compared with those with incomes under $30 000, HRs for discontinuation were 0.88 (95% CI, 0.85-0.92) for those with incomes of $30 001 to $50 000, 0.80 (95% CI, 0.77-0.84) for those with incomes of $50 001 to $80 000, and 0.72 (95% CI, 0.69-0.76) for those with incomes of more than $80 000
Do a quick search on Reddit and youll find plenty of threads discussing improved cycle regularity or, on the flip side, a sudden stop to periods after starting treatment with GLP-1s
PMID: 12 ZabottiADe MarcoGGossecLBaraliakosXAletahaDIagnoccoAet al